Form 4: Olema Pharmaceuticals Director Cyrus Harmon Sells 15,000 Shares

Director Cyrus Harmon sold 15,000 shares of Olema Pharmaceuticals (OLMA) common stock on April 30, 2024, at a weighted average price of $9.51, according to a Form 4 filing with the SEC.

Summary

• On April 30, 2024, Cyrus Harmon, a director of Olema Pharmaceuticals, sold 15,000 shares of common stock.
• The sale was executed at a weighted average price of $9.51 per share, with prices ranging from $9.20 to $9.91.
• Following the transaction, Harmon directly owns 811,283 shares and indirectly owns 122,028 shares through Harmon Family Investors LLC.
• The sale was conducted under a pre-arranged 10b5-1 trading plan adopted on May 16, 2023.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it reports a routine stock sale by a director under a pre-arranged trading plan. It doesn't inherently indicate positive or negative sentiment about the company's prospects.

Industry Context

Insider sales are a common occurrence and are often scrutinized by investors as they can provide insights into management's perspective on the company's valuation and future prospects. However, sales under a 10b5-1 plan are pre-arranged and may not necessarily reflect the insider's current views.

Stakeholder Impact

• The sale of shares by a director could potentially create short-term selling pressure on the stock.
• Shareholders may interpret the sale as a lack of confidence in the company's future prospects, although the 10b5-1 plan mitigates this concern.

Key Dates